The full set of businesses analyzed in our Scrip 100 annual review saw a total profit of $136.8bn in 2016 – and the top 20 pharmas in the sector were responsible for 87% of the industry's gains. Below, we crunch the numbers and provide a quick take on how the biopharma sector performed in 2016.
This year's Scrip 100 edition, which will go live on Dec. 21, includes exclusive features across a broad range of critical industry topics, including a brand-new chapter on patient access...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
